Acetylcholine Receptor Blocking Autoantibody

Last Modified: 2/2/2022 1:01:44 PM

Medical Necessity Documentation:  
Client Notes:  
Patient Preparation:  
Specimen Requirements: 1.0 mL Serum in a SST Gold Top Tube
Collection Instructions:  
Minimum Volume: 0.5 mL
Transport & Storage: Temperature/Stability: 14 days Ambient
14 days Refrigerated
30 daysFrozen
Rejection Criteria: microbially contaminated; gross hemolysis; grossly lipemic
Reference Range: < 15 % of inibition
Critical Ranges:  
Test Comments:  
Methodology: RIA
Clinical Significance: Myasthenia gravis (MG), the most common neuromuscular transmission disorder, is an antibody-mediated autoimmune disease that stems from a loss of acetylcholine receptors (AChR) at neuromuscular junctions. AChR autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR binding autoantibodies are present most frequently in MG and provide the most reliable information for diagnostic screening. A small portion of patients with early onset or ocular restricted MG may only have AChR modulating autoantibodies, thus if AChR binding autoantibodies are absent in a patient with weakness or ocular symptoms consistent with MG, AChR modulating autoantibodies should be ordered. AChR blocking autoantibodies are directed against the neurotransmitter-binding site and may be the only AChR autoantibody in about 1% of MG patients.
Custom Panel: No


Turn Around Time: 3 to 6 days
Days Performed: Sunday, Tuesday, Thursday
Sites Performed: Quest - Chantilly to San Juan Capistrano
PHL Test Code: ACRBA
EPIC Test Code: LAB838
Send Out Test Code: 34459
Alternate Test Names: ACHR Blocking Antibody; Myasthenia Gravis Evaluation
Included Tests:  
CPT Coding: 83519

Go back to the top of the page.